CA2390786A1 - Compositions et procedes de traitement de maladies d'ordre immunologique - Google Patents

Compositions et procedes de traitement de maladies d'ordre immunologique Download PDF

Info

Publication number
CA2390786A1
CA2390786A1 CA002390786A CA2390786A CA2390786A1 CA 2390786 A1 CA2390786 A1 CA 2390786A1 CA 002390786 A CA002390786 A CA 002390786A CA 2390786 A CA2390786 A CA 2390786A CA 2390786 A1 CA2390786 A1 CA 2390786A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
acid sequence
pro
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002390786A
Other languages
English (en)
Inventor
Sherman Fong
Audrey Goddard
Paul J. Godowski
Christopher J. Grimaldi
Austin L. Gurney
Kenneth J. Hillan
Daniel Tumas
Colin K. Watanabe
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/fr
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/fr
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2390786A1 publication Critical patent/CA2390786A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à des compositions contenant de nouvelles protéines et à des procédés utilisant ces compositions pour diagnostiquer et traiter des maladies d'ordre immunologique.
CA002390786A 1999-11-30 2000-11-10 Compositions et procedes de traitement de maladies d'ordre immunologique Abandoned CA2390786A1 (fr)

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
USPCT/US99/28313 1999-11-30
PCT/US1999/028313 WO2000032221A2 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
US17026299P 1999-12-09 1999-12-09
US60/170,262 1999-12-09
US17205999P 1999-12-23 1999-12-23
US60/172,059 1999-12-23
US17548100P 2000-01-11 2000-01-11
US60/175,481 2000-01-11
US17711800P 2000-01-20 2000-01-20
US60/177,118 2000-01-20
USPCT/US00/04342 2000-02-18
PCT/US2000/004342 WO2000078961A1 (fr) 1999-06-23 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
PCT/US2000/014941 WO2000073348A2 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
USPCT/US00/14941 2000-05-30
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
USPCT/US00/23328 2000-08-24
US60/000,000 2000-09-15
PCT/US2000/030873 WO2001040465A2 (fr) 1999-11-30 2000-11-10 Compositions et procedes de traitement de maladies d'ordre immunologique

Publications (1)

Publication Number Publication Date
CA2390786A1 true CA2390786A1 (fr) 2001-06-07

Family

ID=27558595

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002390786A Abandoned CA2390786A1 (fr) 1999-11-30 2000-11-10 Compositions et procedes de traitement de maladies d'ordre immunologique

Country Status (5)

Country Link
EP (1) EP1234036A2 (fr)
JP (4) JP4211966B2 (fr)
AU (1) AU3434601A (fr)
CA (1) CA2390786A1 (fr)
WO (1) WO2001040465A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503730B1 (en) 1997-06-19 2003-01-07 Schering Corporation Nucleic acids encoding a cysteine rich protein
EP1897947B1 (fr) * 1999-12-23 2012-01-18 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US7307153B2 (en) * 1999-12-23 2007-12-11 Genentech, Inc. Antibodies that bind PRO9912
US20030153015A1 (en) 2000-01-20 2003-08-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2003053334A2 (fr) * 2001-12-19 2003-07-03 Genentech, Inc. Compositions et methodes de diagnostic et de traitement de tumeur
US7749695B2 (en) * 2003-03-03 2010-07-06 Alexander Abbas PRO polypeptides for diagnosis of systemic lupus erythematosis
JP2007518404A (ja) * 2003-12-16 2007-07-12 ジェネンテック・インコーポレーテッド 新規な遺伝子破壊、これに関する組成物と方法
US20090317400A1 (en) 2008-05-05 2009-12-24 Krzysztof Masternak Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof
PE20120815A1 (es) 2009-05-05 2012-07-08 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5874230A (en) * 1996-07-10 1999-02-23 Tularik, Inc. Assays using TRAF2-associated protein kinase polypeptides
WO1998011138A1 (fr) * 1996-09-12 1998-03-19 Human Genome Sciences, Inc. Chimiokine alpha-4
AU5383498A (en) * 1996-12-05 1998-06-29 Human Genome Sciences, Inc. Human chemokine beta-13
EP0973896A2 (fr) * 1997-04-10 2000-01-26 Genetics Institute, Inc. Marqueurs secretes de sequence exprimee (sest)
WO1998058061A1 (fr) * 1997-06-19 1998-12-23 Schering Corporation Genes de mammiferes et reactifs associes
JP2002507390A (ja) * 1998-01-30 2002-03-12 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
CA2326001A1 (fr) * 1998-04-24 1999-11-04 Genentech, Inc. Proteines fizz

Also Published As

Publication number Publication date
JP4211966B2 (ja) 2009-01-21
JP2006068007A (ja) 2006-03-16
WO2001040465A2 (fr) 2001-06-07
JP2006197937A (ja) 2006-08-03
JP4226605B2 (ja) 2009-02-18
EP1234036A2 (fr) 2002-08-28
AU3434601A (en) 2001-06-12
JP4242371B2 (ja) 2009-03-25
WO2001040465A3 (fr) 2002-03-21
JP2003530082A (ja) 2003-10-14
JP2008301810A (ja) 2008-12-18

Similar Documents

Publication Publication Date Title
AU2003298607B9 (en) Compositions and methods for the treatment of immune related diseases
US20120035073A1 (en) Compositions and methods for the treatment of immune related diseases
US20110172114A1 (en) Compositions and methods for the treatment of immune related diseases
US20090098131A1 (en) Compositions and methods for the treatment of immune related diseases
CA2503125C (fr) Nouvelle composition et procedes pour le traitement de maladies auto-immunes
CA2498008A1 (fr) Nouvelles composition et methodes servant au traitement de maladies associees au systeme immunitaire
CA2503748A1 (fr) Compositions et procedes de traitement des maladies liees aux cellules k naturelles
US7282570B2 (en) Compositions and methods for the treatment of immune related diseases
AU2009243417A1 (en) Novel compositions and methods for the treatment of immune related diseases
US20110243930A1 (en) Compositions and methods for the treatment of immune related diseases
AU2009200614A1 (en) Compositions and methods for the treatement of immune related diseases
CA2390786A1 (fr) Compositions et procedes de traitement de maladies d'ordre immunologique
US7601514B2 (en) Nucleic acid encoding PRO10268 polypeptides
WO2001066740A2 (fr) Compositions et methodes de traitement de maladies d'origine immune
CA2384055A1 (fr) Compositions et procedes pour le traitement de maladies d'ordre immunologique
US7365157B2 (en) PRO9912 polypeptides
US7344880B2 (en) Nucleic acid encoding PRO9912 polypeptides
AU2007202846B2 (en) Compositions and methods for the treatment of immune related diseases
WO2001019991A1 (fr) Compositions et techniques permettant de traiter des maladies d'origine immunologique
EP1878795A2 (fr) Compositions et procédés pour le traitement de maladies liées au système immunitaire
WO2001092331A2 (fr) Compositions et methodes de traitement de maladies d'origine immune
AU2012233034A1 (en) Novel compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued